Most Read Articles
10 Feb 2019
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
14 Jun 2017
The use of spot urine appears to be unhelpful in estimating 24-hour urinary sodium excretion at the individual level due to its poor performance with regard to misclassification, according to a recent study.
6 days ago
Physician-guided cessation of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is safe in patients presenting with acute coronary syndrome, a recent study has shown.
22 Mar 2017
Exosomal microRNAs (miRNAs) in the serum are potential diagnostic biomarkers for Kawasaki disease (KD), a new study shows.

Losartan reduces blood pressure in euvolemic hypertension after dialysis

24 Dec 2017
The American Heart Association has lowered the value for diagnosing hypertension to 130/80 from the previous 140/90.

Losartan at 50 mg is effective in reducing blood pressure in patients with postdialysis euvolemic hypertension, a recent study has shown.

Researchers performed a multicentre, randomized, prospective, single-blind trial including 88 postdialysis euvolemic patients with systolic blood pressure >140 mm Hg who were then randomized to receive either standard antihypertensive therapy or losartan alone or in combination with antihypertensives.

In the standard-arm group, blood pressure improved from a predialysis baseline value of 167.5±18.2 to 162.4±10.2 mm Hg after the 12-month follow-up, resulting in a significant drop of 5.1 mm Hg (p=0.003).  In comparison, blood pressure in the losartan group also significantly dropped from 168.65±16.33 mm Hg at baseline to 158.45±10.65 mm Hg after 12 months (difference, 10.23 mm Hg; p<0.001).

On the other hand, postdialysis blood pressure was only significantly improved in the losartan group, with the baseline value of 156.34±13.40 mm Hg dropping to 149.73±10.21 mm Hg after 12 months. The difference of 6.6 mm Hg reached statistical significance (p<0.001).

There were more deaths in the standard arm than in the losartan group (13.6 vs 4.5 percent), resulting in respective survival probabilities of 84 and 95 percent. However, Kaplan-Meier analysis showed no significant difference in survival between the groups.

In terms of adverse events, losartan was found to be related to two cases of hyperkalaemia, four cases of coughs, three cases of dizziness, and one case of dyspepsia.

Finally, simple linear regression showed that diabetes was significantly associated with postdialysis systolic blood pressure in both the standard-arm (p=0.03) and losartan (p=0.02) treatment groups. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
10 Feb 2019
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
14 Jun 2017
The use of spot urine appears to be unhelpful in estimating 24-hour urinary sodium excretion at the individual level due to its poor performance with regard to misclassification, according to a recent study.
6 days ago
Physician-guided cessation of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is safe in patients presenting with acute coronary syndrome, a recent study has shown.
22 Mar 2017
Exosomal microRNAs (miRNAs) in the serum are potential diagnostic biomarkers for Kawasaki disease (KD), a new study shows.